Table 1. Cases of East Asian patients with squamous cell carcinoma harboring ALK/ROS1 fusions.

Author	Year	Race	Gender	Age (years)	Pathology	Smoking status	Stage	Molecular alteration	treatment	Best response	PFS (months)	Reference
Wang et al.	2014	Chinese	Female	55	SQCC	Never	IV	ALK fusion	Crizotinib	Partial response	5.8+	(118)
Zhang et al.	2015	Chinese	Female	55	SQCC	Never	IV	ALK fusion	Crizotinib	Partial response	6	(119)
Wang et al.	2016	Chinese	Female	37	SQCC	Never	IIIB	ALK fusion	Crizotinib	Partial response	9+	(120)
Mamesaya et al.	2017	Japanese-Brazilian	Female	52	SQCC	Never	IV	ALK fusion	Alectinib	Partial response	11+	(121)
Li et al.	2017	Chinese	Female	47	SQCC	Never	IV	ALK-ROS1 fusion	Crizotinib	Partial response	5	(122)
Tamiya et al.	2015	Japanese	Male	78	SQCC	Ever	Unknown	ALK fusion	Alectinib	Stable disease	1.5+	(123)

PFS, progression-free survival; SQCC, squamous cell carcinoma.